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Abstract
Objective: Endothelial progenitor cells (EPC) are committed to transform into EC promoting vasculogenic ischemic repair.
Anti-endothelial cells (AECA) have been described in various disorders with an associated vascular damage. Herein, we
explored a novel circulating population of IgG reactive with EPC, in patients with differential risk profile for atherosclerotic
vascular disease.
Approach and Results: A novel cyto-ELISA system was established where the coated cells were late outgrowth EPC. Levels
of anti-EPC antibodies were determined in 100 subjects and differential risk score for atherosclerosis, as well as to circulating
EPC levels and the inflammatory markers IL-6 and C-reactive protein. To study endothelial cell (EC) activating properties, sera
were tested for their ability to induce VCAM-1 expression in a cell ELISA system. Detectable levels of anti-EPC antibodies,
that correlated with age, Framingham risk score and CRP concentrations but did not associate with levels of LDL, HDL,
hypertension or diabetes, were detected. Anti-EPC antibodies were distinct from EC binding antibodies as shown by
competitive inhibition studies, and have been positively correlated with the extent of EC activation manifested by in vitro
VCAM-1 expression.
Conclusion: This is the first study showing a newly defined subgroup of self-antibodies binding EPC and associating
positively with the Framingham risk score. Further studies are required to characterize and test this interesting subset of EPC
binding autoantibodies and their potential significance.
Citation: George J, Matucci-Cerinic M, Bar I, Shimoni S (2014) Circulating Autoantibodies to Endothelial Progenitor Cells: Binding Characteristics and Association
with Risk Factors for Atherosclerosis. PLoS ONE 9(6): e97836. doi:10.1371/journal.pone.0097836
Editor: Rudolf Kirchmair, Medical University Innsbruck, Austria
Received November 15, 2013; Accepted April 24, 2014; Published June 19, 2014
Copyright:  2014 George et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* Email: jgeorge@bezeqint.net
Introduction
Endothelial progenitor cells (EPC) are a subset of hematopoietic
progenitors that circulate in the peripheral blood and play an
active role in maintaining the integrity of the endothelium as well
as promoting the recovery from various insults that result in tissue
ischemia [1,2]. The number and function of EPC, namely their
ability to differentiate into endothelial cells, to produce/secrete a
panel of proliferative cytokines and to transmigrate through the
endothelial lining determine their vasculogenic capacity.
There are multitude of factors that control the number and
function of EPC, thereby dictating their efficacy in promoting
tissue healing. These factors include cytokines that promote their
proliferation and crossing of the bone marrow barrier as well as
those factors facilitating their transmigration to the affected organs
and triggering peripheral senescence [1,2].
The seminal work Asahara et al [3] back in 1997, outlining the
presence of circulating EPC, was followed by numerous studies
that supported this observation and further demonstrated their
presence in various pathological states as well as their therapeutic
potential [1–4]. Several reports have shown that in patients with
risk factors for atherosclerotic vascular disease, the numbers of
peripheral EPC are significantly reduced [5,6]. However, the
question of whether this finding is a result or an causal contributor
to atherosclerosis has not been resolved.
Autoantibodies to cellular components have been described in
several conditions. Examples include anti-heart autoantibodies in
patients with post myocardial insults such as pericarditis [7,8], anti
smooth muscle [9] and anti parietal [10] cell antibodies. Of
particular interest is the subgroup of autoantibodies reactive with
endothelial cells (anti endothelial cell antibodies; AECA) that have
been demonstrated in various immune mediated disorders, the
most commonly described of which is systemic sclerosis [11], in
particular those with pulmonary hypertension [12], where the
prevalence of AECA reaches nearly 80%. With regard to
atherosclerosis, small studies have not yielded conclusive results
as to the prevalence of AECA [12,13]). This finding has prompted
researchers to hypothesize that AECA may not only stand as
markers of vascular damage but may also be pathogenic and
contribute to the pathological features of the vascular damage
[14]. Indeed, there are several reports where AECA from patients
with various autoimmune disorders, even those with lower affinity,
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were found capable of inducing endothelial cell activation in vitro
[14,15].
In this study, we explored the possibility that EPC binding
antibodies are present in the peripheral circulation. This is the first
report documenting the presence of these autoantibodies, their
binding properties and their association with risk factors for
atherosclerotic vascular disease.
Methods
We studied 100 volunteers (Table 1), older than 25 years of age
(median 61 years (27–90)), with and without conventional
atherosclerotic cardiovascular risk factors. Subjects were evaluated
for traditional risk factors and the Framingham risk factor score
was calculated as described [12]. Subjects with any type of
malignant or hematologic disorder or those taking anti-inflamma-
tory agents were excluded. All enrolled subjects underwent a
detailed assessment of cardiovascular risk. This study was
approved by the Kaplan Medical center institutional ethics
committee. All patients provided written informed consent for
participating in the study, including the collection and generation
of the cell lines.
Table 1. Baseline characteristics of the study population.
N=100
Age (years) 61 (27–90)
Male/Female 55/45
DM (n) 19
HTN (n) 54
Hyperlipidemia (n) 55
HG (g/dL) 13.5661.5
WBC 7.0262
Platelets 279670
Creatinine (mg/dL) 0.8860.19
Total cholesterol (mg/dL) 177634
TG (mg/dL) 128669
HDL (mg/dL) 51614
LDL (mg/dL) 100629
Framingham risk score 860.8
DM-Diabetes mellitus, HTN-Hypertension, HG-Hemoglobin, WBC-White blood
cells, TG-triglyceride, HDL-high density lipoprotein, LDL-low density lipoprotein.
doi:10.1371/journal.pone.0097836.t001
Figure 1. Analysis of late outgrowth EPC and binding characteristics of circulating anti-EPC antibodies. Late outgrowth EPC were
obtained from several healthy individuals as described in methods. FACS was used test for surface marker expression (Left panel). To determine if
antibodies to EPC are identical to AECA we performed competitive inhibition studies where anti-EPC or AECA were preincubated with EPC or AECA at
different ratios and their binding to sold phase bound EPC or HUVEC tested by ELISA as described in methods (Right panel).
doi:10.1371/journal.pone.0097836.g001
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ELISA for Detection of AECA and Anti-EPC
Autoantibodies
Human umbilical vein endothelial cells (HUVEC) were
produced and grown as previously described and serum levels of
IgG AECA were determined by ELISA as shown [13].
In brief, HUVEC were seeded in gelatin-coated 96-well
microtiter plates at 2.56104 cells per well and allowed to grow
to confluence for 1 or 2 days. Since fixation was required, after
washing with fresh growing medium the wells were covered with
100 ml Glutaraldehyde solution (3%, Ph 7.2, Paraformaldehyde
2.5%, Cacodylate buffer 0.1 M) at a final concentration of 0.1% in
PBS. Cells were washed 3 times with HBSS and incubated with a
blocking buffer (HBSS: 0.5% BSA, 150 ml per well) for 30 min at
37uC to prevent non-specific binding of antibody. After additional
washing with HBSS, the endothelial cells were exposed to 100 ml
diluted serum (dilutions 1:25 in HBSS 20.2% BSA) for 90 min at
RT (or overnight at 4uC) with slow shaking. Cells were washed
again and incubated with 100 ml of the second antibody, alkaline
phosphatase-conjugated goat anti-human IgG (Jackson Immu-
noResearch Laboratory, WestGrove, PA) diluted 1:10,000 in
HBSS 20.2% BSA for 60 min at RT with shaking. After washing
3 times, 100 ml of 1 mg/ml p-nitrophenyl phosphate in 50 mmol/l
carbonate buffer containing 1 mmol/l MgCl2 pH 9.8 was added
as a substrate. The reaction was stopped after 30 min by adding
50 ml of 1 mol/l NaOH. The OD was read at 405 nm in an
ELISA plate reader (EAR400 AT, SLT-Labinstruments, Austria).
We used late-outgrowth EPC as the target cell population for
determination of anti-EPC antibodies as this population most
likely reflects true circulating EPC [16]. The blood mononuclear
cell fraction from healthy donors was collected by Ficoll (Pancoll,
Dutcher, France) density gradient centrifugation and resuspended
in endothelial growth medium (EGM-2) (Lonza, Verviers,
Belgium). Cells were then seeded on collagen-precoated 12-well
plates (BD Biosciences) at 26107 cells per well and stored at 37uC
and 5% CO2. After 24 hours of culture, adherent cells were
washed once with phosphate-buffered saline and cultured in
EGM-2 with daily changes until the quantification. Colonies of
endothelial cells appeared between 9 and 26 days of culture and
were identified as well-circumscribed monolayers of cells with a
cobblestone appearance. The next steps of the ELISA were
performed as described for the AECA ELISA.
Determination of Circulating EPC and Late Outgrowth
EPC by FACS
The number of circulating EPCs was assessed by FACS analysis
by staining 1 million cells for two-color FACS analysis employing
the following monoclonal antibodies: fluorescein isothicyanate-
anti-CD34 (IQ products) and allophycocyanin-anti VEGF-recep-
tor 2 (KDR, R&D systems). The various EPC phenotypes assessed
were CD34+ and CD34+KDR+.
Late outgrowth EPC were characterized by the expression of
several EPC markers: CD34-PE, KDR-APC, CD31-FITC and
CD133- biotinylated (Miltenyi biotec), and secondary Rabbit anti
mouse PerCP (Santa Cruz).
Competitive Inhibition of Binding of Anti-EPC Antibodies
In order to determine whether anti-EPC antibodies are actually
identical to AECA were performed competitive inhibition studies.
For this purpose, we chose several sera with high levels EPC
binding antibodies. Sera (1:25) were incubated with different
concentrations of HUVEC overnight and evaluated using the
above described anti-EPC ELISA.
EC Activation In vitro as Determined by VCAM-1
Expression Employing ELISA
HUVEC or Late outgrowth EPC were grown onto 96-well
plates washed and fixed with 0.1% glutaraldehyde, and treated
with PBS containing 0.2% Triton X-100 to permeabilize the cell
membrane. Sera from all subjects diluted 1:2 were added to the
plates overnight. Also, 6 total IgG fractions with HUVEC binding
and non HUVEC binding properties were purified from the
respective sera using protein G columns and used in concentra-
tions of 10 micrograms/milliliter. Plates were blocked with 3%
BSA and incubated with biotinylated anti-human VCAM-1
(PharMingen) (1 mg/mL) for 1 hour. Cells were then exposed to
streptavidin alkaline phosphatase (1:5000 dilution) and the
appropriate substrate.
Serum Biomarker Analyses
The collected blood samples were layered over previously
prepared Ficoll gradients.
Five milliliters of the serum were removed and stored in a
properly identified freezer (270uC).
Serum levels of IL-6 and VEGF were assessed by ELISA with
the DuoSet kit (R&D Systems Minneapolis, MN, U.S.) according
to manufacturer’s instructions and the analysis protocol.
The serum levels of high sensitivity CRP (hsCRP) were
measured by the CardioPhase hsCRP Reagent (Siemens Medical
Solutions Diagnostics) according to manufacturer’s instructions.
Statistical Analysis
Continuous data are presented as medians and inter quartile
ranges (25th–75th percentiles) for skewed distributed variables or as
mean ± SD when normally distributed, and categorical data are
presented as absolute numbers and respective percentages. Chi-
square tests were used for categorical variables and Student’s t test
for continuous variables. Correlation analyses between various
Figure 2. Association between anti-EPC levels and risk factors for atherosclerotic vascular disease. Levels of anti-EPC abs were
determined by cyto ELISA as described in methods. The levels were correlated with the presence of individual risk factors (Age, gender, presence of
hypertension and diabetes mellitus) and cumulative Framingham score.
doi:10.1371/journal.pone.0097836.g002
Table 2. Correlation between anti EPC abs, laboratory results
and biomarkers.
R P
Hg 20.15 0.16
WBC 20.03 0.9
Platelets 20.06 0.58
Creatinine 0.09 0.37
Total cholesterol 20.15 0.15
TG 20.14 0.19
hsCRP 0.29 0.004
VEGF 0.04 0.7
IL-6 0.02 0.8
doi:10.1371/journal.pone.0097836.t002
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parameters were provided using Pearson correlation coefficients.
Analyses were considered significant at p#0.05.
Results
Late outgrowth EPC were used for the cyto ELISA as the target
cells for the detection of anti-EPC abs as they have been shown to
be the most accurate cellular subset to mirror EPC. The markers
expressed by this cell population using FACS were: 8.3±5.7% to
CD34, 12.8±5.4% to CD31, 1.9±1.4% to KDR and 16.1±5.6%
to CD133 (Figure 1).
To determine if anti-EPC antibodies are actually AECA were
performed competitive inhibition studies. We have found that
preincubation of serum harboring anti EPC abs with HUVEC
reduced the binding to solid phase bound EPC only by
approximately 7% whereas EPC reduced them significantly,
suggesting most of these populations are non overlapping.
Anti-EPC antibody level was associated with the age of the
subjects (Figure 2), however no difference in the levels was evident
between male versus females nor have been found among diabetics
compared with non-diabetic and for hypertensives versus non
hypertensives (Figure 2).
Furthermore, levels of anti-EPC abs did not correlate with LDL,
TG or HDL levels (Table 2). No association was also detected
between antibody levels and IL-6 or VEGF circulating concen-
trations. However a positive correlation was evident between the
levels of anti-EPC abs and circulating hsCRP (Table 2).
A significant correlation was found between the levels of anti-
EPC abs and the cumulative Framingham score (Figure 2).
Interestingly, no correlation was found between levels of anti-EPC
abs and circulating EPC defined as CD34+KDR positive cells
(Figure 3A).
Aiming to explore whether anti-EPC abs have potential
functional properties, we tested the effect of sera from all subject
for their ability to induce VCAM-1 expression on solid phase
bound HUVEC and EPC (Figure 3B&C). Indeed, we have found
a correlation between levels of anti EPC abs and the extent of EC
activation as measured by VCAM-1 expression by HUVEC. No
such correlation was evident with regard to VCAM-1 expression
on EPC. Mean OD values from HUVEC binding anti-EPC IgG
fractions exhibited a significant mean 46% increase in VCAM-1
expression as compared with IgG fractions obtained from non-
HUVEC binding sera.
Discussion
This is the first study documenting the presence of autoantibody
reactive with EPC in patients with a graduated atherosclerotic risk
profile. We have found that circulating autoantibodies that bind
EPC can be found by a simple ELISA similar to that developed for
AECA.
AECA has been detected in various connective tissue diseses
(SLE, antiphospholipid syndrome, systemic sclerosis) and vasculit-
ides ect [11,14,15,17]. The main obstacle to studying the true
nature of AECA, similar to other cell-binding autoantibodies, is
their heterogeneity in terms of binding epitopes as well as the lack
of standardization of their detection method. With regard to
atherosclerosis, small studies have not yielded conclusive results as
to the prevalence of AECA [13,18], yet patients with early or
Figure 3. Association of anti-EPC abs with circulating EPC and
with VCAM-1 expression on HUVEC and EPC. Serum anti-EPC
levels were correlated with circulating CD34+KDR+EPC (A) and with
surface expression of the adhesion molecule VCAM-1 on HUVEC (B) and
late outgrowth EPC (C).
doi:10.1371/journal.pone.0097836.g003
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masked hypertension do possess higher titers of these circulating
autoantibodies [19,20].
The interesting aspect of AECA is their potential pathogenic
role and in particular their ability to induce endothelial activation
by triggering surface expression of adhesion molecules such as
VCAM-1 on the surface of EC [14,15]. Indeed, considerable data
has been provided to support this function of AECA [14].
The cumulative observations with regard to AECA led us to
speculate that similar to endothelial binding antibodies, anti-EPC
autoantibodies are also present. The data we demonstrate herein
with regard to circulating EPC and their association with risk
factors for atherosclerosis are much more robust that those that
exist with circulating AECA and show that lower anti-EPC
antibody levels are associated with risk factors of vascular disease
[5,6]. Thus, it can be assumed that the detection of such
circulating antibodies may be at least equally important to those
of circulating EPC and to AECA.
One of the major hurdles in the study of EPC relates to the wide
spectrum of binding antigens expressed by these cells. Accordingly,
we have previously shown that different methods used to
characterize EPC do not correlate with each other, and the
method more closely associated with circulating levels of the EPC-
promoting-VEGF is the CD34+KDR+ subpopulation [21].
Herein, we have used for the ELISA, EPC that were recently
recognized as true endothelial progenitors, namely late outgrowth
EPC and also verified by FACS their co-expression of CD34 and
CD31.
It is likely that a portion of anti-EPC antibodies cross-react with
endothelial cells as EPC develop into EC. Our competitive
inhibition studies support this contention, yet do suggest that
AECA and anti-EPC abs are not an identical cellular subsets.
The titers of autoantibody reactive with EPC were increased in
subjects with the higher Framingham scores (Figure 2) and higher
hsCRP levels. Such a finding has not been described for AECA
suggesting that a closer association of anti-EPC antibodies with
atherosclerosis may exist. This is further supported by the
association that was evident between antibody levels and age, a
finding that may also be amplified by the well acknowledged
increase in total IgG levels with aging. Interestingly, anti-EPC
antibodies are not correlated with EPC numbers suggesting
differential control mechanisms governing their production
although both correlate with risk factor index for atherosclerosis.
An interesting and provocative question with regard to anti-
EPC autoantibodies relate to their potential pathogenic role. For
AECA, it has been suggested that several properties could mediate
their pathogenic potential including, endothelial activation
[14,15], enhanced coagulation [22] and even triggering EC
apoptosis [23]. Although, we cannot provide definite answers to
this question, we did notice that sera from subjects with higher
titers of anti-EPC antibodies were capable of producing a more
pronounced effect on VCAM-1 expression on EC in vitro
(Figure 3B). If this is occurring in vivo, it could be assumed that
EPC autoantibodies may have a role in promoting endothelial
dysfunction, with subsequent contribution to inflammatory disor-
ders and atheroma formation. Indeed, Del Papa et al [23] have
shown for the first time, that IgG fractions obtained from bone
marrow plasma of scleroderma patients exhibited endothelial
binding activity that was associated with the extent of EPC
apoptosis. In contrast with these observations, anti-EPC abs could
represent an epiphenomenal autoimmune response to EPC
undergoing apoptotic cell death in vivo. We have recently provided
evidence that such a population of apoptotic progenitors is present
in vivo in patients with coronary atherosclerosis [24] and heart
failure [25], where oxidative stress is heightened.
In conclusion, we provide for the evidence for the presence of
autoantibodies reactive with circulating EPC and that the level of
these antibodies correlated with the Framingham risk score for
atherosclerotic vascular disease. Further studies are required to test
the importance of anti-EPC autoantibodies and their potential
pathogenic role in promoting vascular dysfunction.
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